12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
14:56The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb
Future Value
10:42A Postoperative Evaluation Guideline for Computer-Assisted Reconstruction of the Mandible
Guidelines in Case of a Laboratory Emergency
07:33Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 20, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
J Wade Atkins1, Kamille West2, Kimberly A Kasow3
1Department of Transfusion Medicine, Clinical Center, NIH, 10 Center Drive, MSC-1184, Building 10, Room 1C/711B, Bethesda, MD 20892-1184, USA.
Human cell-based biologics offer therapeutic potential but carry risks from manipulation. Collaboration and regulatory advancements like the 21st Century Cures Act are crucial for safe clinical development and patient access.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: